{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T20:00:00Z","timestamp":1759694400925},"reference-count":5,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.medcli.2020.09.017","type":"journal-article","created":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T00:42:01Z","timestamp":1611967321000},"page":"403-405","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunomodulation for Pompe Disease with high sustained antibodies against enzyme replacement therapy"],"prefix":"10.1016","volume":"157","author":[{"given":"Javier","family":"Blasco-Alonso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Gil-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso Lend\u00ednez","family":"Jurado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel Yahyaoui","family":"Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2020.09.017_bib0030","first-page":"269","article-title":"Clinical guidelines for infantile-onset Pompe disease","volume":"63","author":"Pascual-Pascual","year":"2016","journal-title":"Rev Neurol"},{"key":"10.1016\/j.medcli.2020.09.017_bib0035","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/eci.12.40","article-title":"Immune modulation in Pompe disease treated with enzyme replacement therapy","volume":"8","author":"Banugaria","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.medcli.2020.09.017_bib0040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet Med"},{"key":"10.1016\/j.medcli.2020.09.017_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2013.03.002","article-title":"B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease","volume":"163","author":"Elder","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.medcli.2020.09.017_bib0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/gim.2012.110","article-title":"Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease","volume":"15","author":"Banugaria","year":"2013","journal-title":"Genet Med"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775320307557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775320307557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T20:09:16Z","timestamp":1634587756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775320307557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":5,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0025775320307557"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2020.09.017","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulation for Pompe Disease with high sustained antibodies against enzyme replacement therapy","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2020.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}